May 26, 2022
CEO Giroir announces Altesa’s IND for vapendavir has the FDA green light for clinical study at AdvanSE Conference ATLANTA – May 26, 2022 – Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
May 25, 2022
George Painter, Emory Professor and CEO of DRIVE, awarded $52 million to co-lead Antiviral Countermeasures Development Center ATLANTA, May 25, 2022 – Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
Feb 10, 2022
https://www.altesabio.com/wp-content/uploads/2022/02/NR_ALTESA_LAUNCHES_OPS_02.10.2022.pdf
Jul 7, 2021
https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-exclusive-worldwide-license-agreement-altesa
Recent Comments